Rossella E Nappi1, Santiago Palacios2, Nico Bruyniks3, Martire Particco4, Nick Panay5. 1. Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, University of Pavia, Pavia, Italy. 2. Palacios Institute of Women's Health, Madrid, Spain. 3. BrInPhar Ltd, Iver Heath, United Kingdom. 4. Shionogi Ltd, London, United Kingdom. 5. Imperial College London, London, United Kingdom.
Abstract
OBJECTIVE: This subanalysis of the European Vulvovaginal Epidemiology Survey study aimed to assess the correlation of vulvovaginal atrophy (VVA) symptoms and severity, when confirmed by objective gynecologic examination, with the quality of life of postmenopausal women. METHODS: Women aged 45 to 75 years with confirmation of last menstrual period more than 12 months before, who attended menopause or gynecology centers, were included. Those women had at least one VVA symptom filled in a group of questionnaires, including EuroQol-EQ-5D-3L and Day-to-Day Impact of Vaginal Aging (DIVA). To confirm the VVA diagnosis, an objective gynecologic examination was also performed. RESULTS: Of a total of 2,160 evaluable women, 66.3%, 30.5%, and 11.2% suffered from severe vaginal, vulvar, and urinary symptoms, respectively. VVA was confirmed in more than 90% of the participants. Mean (±SD) EQ-5D-3L score was 0.892 ± 0.144 and mean (±SD) score on the associated visual analog scale was 71.7 ± 16.0. Mean (±SD) DIVA score was 0.922 ± 0.653. For both EQ-5D-3L and DIVA, the overall scores and most of the dimensions/components were statistically significantly worse for women with severe VVA symptoms (vulvar and urinary) compared with women not affected by severe symptoms. Quality of life questionnaires showed worse scores in women where the diagnosis of VVA was confirmed by gynecologic examination. CONCLUSIONS: Severe VVA symptoms showed a direct association with worse quality of life in postmenopausal women. This important effect on the quality of life of many women should be recognized as equivalent to those from other conditions and pathologies of which there is greater awareness.
OBJECTIVE: This subanalysis of the European Vulvovaginal Epidemiology Survey study aimed to assess the correlation of vulvovaginal atrophy (VVA) symptoms and severity, when confirmed by objective gynecologic examination, with the quality of life of postmenopausal women. METHODS:Women aged 45 to 75 years with confirmation of last menstrual period more than 12 months before, who attended menopause or gynecology centers, were included. Those women had at least one VVA symptom filled in a group of questionnaires, including EuroQol-EQ-5D-3L and Day-to-Day Impact of Vaginal Aging (DIVA). To confirm the VVA diagnosis, an objective gynecologic examination was also performed. RESULTS: Of a total of 2,160 evaluable women, 66.3%, 30.5%, and 11.2% suffered from severe vaginal, vulvar, and urinary symptoms, respectively. VVA was confirmed in more than 90% of the participants. Mean (±SD) EQ-5D-3L score was 0.892 ± 0.144 and mean (±SD) score on the associated visual analog scale was 71.7 ± 16.0. Mean (±SD) DIVA score was 0.922 ± 0.653. For both EQ-5D-3L and DIVA, the overall scores and most of the dimensions/components were statistically significantly worse for women with severe VVA symptoms (vulvar and urinary) compared with women not affected by severe symptoms. Quality of life questionnaires showed worse scores in women where the diagnosis of VVA was confirmed by gynecologic examination. CONCLUSIONS: Severe VVA symptoms showed a direct association with worse quality of life in postmenopausal women. This important effect on the quality of life of many women should be recognized as equivalent to those from other conditions and pathologies of which there is greater awareness.
Authors: Michaela Gabes; Gesina Kann; Julia von Sommoggy; Petra Stute; Christian J Apfelbacher Journal: BMC Womens Health Date: 2021-11-08 Impact factor: 2.809
Authors: Susana Garcia de Arriba; Lisa Grüntkemeier; Manuel Häuser; Theodor W May; Clarissa Masur; Petra Stute Journal: PLoS One Date: 2022-05-12 Impact factor: 3.240
Authors: Jesús Lázaro-Carrasco de la Fuente; Marcos Cuerva González; Silvia González Rodríguez; Juan Luis Delgado Marín; Carmen Cuevas Castillo; Concepción Nieto Magro Journal: J Menopausal Med Date: 2022-08
Authors: Carolyn J Gibson; Alison J Huang; Joseph C Larson; Caroline Mitchell; Susan Diem; Andrea LaCroix; Katherine M Newton; Susan D Reed; Katherine A Guthrie Journal: Am J Obstet Gynecol Date: 2020-01-15 Impact factor: 8.661